Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Amphastar P(AMPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AMPH
11/02/2026: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Amphastar Pharmaceuticals is a specialized manufacturer of complex generic and proprietary injectable, inhalation, and intranasal products. The company has a leading position in niche areas where it leverages its vertical integration, from active ingredient development to final manufacturing, to maintain margins. Its core growth story centers on a consistent pipeline of new complex drug approvals and the integration of acquired branded products like Baqsimi. Primary risks include regulatory challenges, price competition in the generic sector, and reliance on a limited number of high-value products. It may best suit growth-oriented investors looking for exposure to specialty pharma, provided they monitor regulatory and FDA inspection outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company shows consistent revenue and margin expansion through a robust pipeline of complex drug filings. |
| Momentum investor | Strong fit while signal remains positive | The stock has demonstrated strong price trends driven by successful product launches and improved profitability. |
| Value investor | Mixed fit | While valuations have expanded with growth, the stock may not meet traditional deep-value criteria. |
| Dividend investor | Weak fit | Amphastar does not pay a dividend, prioritizing capital allocation toward R&D and acquisitions. |
| Low-risk investor | Weak fit | Exposure to pharmaceutical regulation and product concentration makes this a higher-volatility equity. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech and specialty pharma stocks often react sharply to regulatory news and clinical trial outcomes. |
| Valuation risk | Medium | Growth expectations are priced into the stock, leaving little margin for error if product launches face delays. |
| Competition risk (Generic injectables) | High | The entry of new low-cost competitors can rapidly erode profit margins for established generic products. |
| Business quality | Medium | Strong vertical integration provides a competitive edge, though reliance on a few key products impacts overall quality stability. |
| Dividend income | Low / none | The company does not provide income through dividends, making it unsuitable for income-focused portfolios. |
| Execution risk | Medium / high | Success is heavily dependent on the ability to navigate complex FDA approval processes and manage large-scale manufacturing operations. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -49.72% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.18B USD | Price to earnings Ratio 16.4 | 1Y Target Price 22.5 |
Price to earnings Ratio 16.4 | 1Y Target Price 22.5 | ||
Volume (30-day avg) 447.6K shares | Beta 0.9 | 52 Weeks Range 16.64 - 29.52 | Updated Date 11/01/2026 |
52 Weeks Range 16.64 - 29.52 | Updated Date 11/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.69 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Generic Pharmaceutical Products | Injectables and other high-complexity generic drugs sold to hospitals and pharmacies. | This is the core steady-state business providing the bulk of revenue through high-volume, regulated medical products. |
| Proprietary Products | Branded items like Primatene Mist and Baqsimi. | These products offer higher margins and brand recognition, serving as a key differentiator for the company. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate 0.8 | Actual - |
Profitability
Profit Margin 10.76% | Operating Margin (TTM) 21.6% |
Management Effectiveness
Return on Assets (TTM) 5.11% | Return on Equity (TTM) 10.3% |
Valuation
Trailing PE 16.4 | Forward PE - | Enterprise Value 1.58B | Price to Sales(TTM) 1.62 |
Enterprise Value 1.58B | Price to Sales(TTM) 1.62 | ||
Enterprise Value to Revenue 2.16 | Enterprise Value to EBITDA 8.18 | Shares Outstanding 42.54M | Shares Floating 31.29M |
Shares Outstanding 42.54M | Shares Floating 31.29M | ||
Percent Insiders 30.81 | Percent Institutions 68.48 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.